Climb Bio, Mabworks report Phase 1 data for IgA nephropathy antibody CLYM116/MIL116Oct 23Clinical readoutClimb Bio, Inc.
Vertex registers Phase 3b trial comparing povetacicept and sibeprenlimab in IgA nephropathyOct 22Trial updatepovetaciceptsibeprenlimab
Climb Bio reports Phase 1 data for anti-APRIL antibody CLYM116 in IgA nephropathy programSep 3Clinical readoutClimb Bio, Inc.